Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Increase in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 497,000 shares, a growth of 228.5% from the November 30th total of 151,300 shares. Currently, 5.6% of the shares of the stock are sold short. Based on an average daily volume of 1,660,000 shares, the short-interest ratio is currently 0.3 days.

Windtree Therapeutics Stock Performance

Windtree Therapeutics stock opened at $0.32 on Friday. The business’s fifty day moving average is $0.55 and its two-hundred day moving average is $3.38. The firm has a market cap of $2.83 million, a P/E ratio of -0.02 and a beta of 0.54. Windtree Therapeutics has a 52 week low of $0.29 and a 52 week high of $14.75.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and issued a $7.00 target price on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.